Facility Investments, Earnings Release Schedules, Definitive Agreements, Patient Enrollments, and Clinical Trial Updates - Analyst Notes on Novo Nordisk, HealthSouth, AMRI, Abiomed, and Geron

NEW YORK, March 27, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Novo Nordisk A/S (NYSE: NVO), HEALTHSOUTH Corp. (NYSE: HLS), Albany Molecular Research Inc. (NASDAQ: AMRI), Abiomed Inc. (NASDAQ: ABMD), and Geron Corporation (NASDAQ: GERN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Novo Nordisk A/S Analyst Notes 

On March 14, 2014, Novo Nordisk A/S (Novo Nordisk) reported a DKK550 million (or $100 million) investment in a new research and development facility in Bagsværd, Denmark for increasing its drug development capacity. The Company stated that the purification plant will enhance its capacity to produce active pharmaceutical ingredients for a growing number of diabetes drugs under development. Novo Nordisk informed that the pilot plant will be fully operational by late 2016 and will be run by CMC Supply (Chemistry, Manufacturing and Control Supply) - a unit within Novo Nordisk R&D. The full analyst notes on Novo Nordisk A/S are available to download free of charge at:

http://www.AnalystsReview.com/03272014/NVO/report.pdf

--

HEALTHSOUTH Corp. Analyst Notes 

On March 20, 2014, HEALTHSOUTH Corporation (HealthSouth) announced that it will report its Q1 2014 financial results on April 28, 2014, after the market close. The Company added that in conjunction with the earnings release, it will host an investor conference call at 9:00 a.m. ET on April 29, 2014, Tuesday, to discuss the results. Additionally, HealthSouth stated that the webcast of the conference call, as well as its replay, will be available at the Company's website. The full analyst notes on HEALTHSOUTH Corp. are available to download free of charge at:

http://www.AnalystsReview.com/03272014/HLS/report.pdf

--

Albany Molecular Research Inc. Analyst Notes 

On March 24, 2014, Albany Molecular Research Inc. (AMRI) announced the signing of a definitive agreement for acquisition of all the outstanding shares of Cedarburg Pharmaceuticals, Inc. (Cedarburg) for $38.2 million in cash, in a transaction valued at $41 million. Commenting on the acquisition, William S. Marth, AMRI's President and CEO, stated, "We are very excited to be joining efforts with Cedarburg as they bring a unique blend of expertise in complex API, a scalable business infrastructure and extensive customer relationships that will augment our existing capabilities and services. This transaction represents an important first step in building out our API capabilities, broadens our offerings and customer base and provides us with an ideal platform to pursue additional value creation opportunities." The Company informed that it expects the transaction to close in early April 2014. AMRI stated that the acquisition is expected to add between $13 million and $14 million to its 2014 revenue, based on the anticipated timing of the close. The Company added that it also anticipates the acquisition to be accretive to its 2014 adjusted diluted EPS in the range of $0.06 to $0.07 per share. The full analyst notes on Albany Molecular Research Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03272014/AMRI/report.pdf

--

Abiomed Inc. Analyst Notes 

On March 20, 2014, Abiomed, Inc. (Abiomed) announced that it has completed the patient enrollment in RECOVER RIGHT, an Investigational Device Exemption (IDE) study of Impella® RP (Right Peripheral). The Company stated that the trial was designed to enroll 30 patients, at 15 sites, for up to 14 days of circulatory support. Commenting on the enrollment completion, Michael R. Minogue, Chairman, President and CEO of Abiomed stated, "We are extremely grateful for the support from the study's principal investigators, Dr. Mark Anderson, at Einstein Medical Center Philadelphia and Dr. William O'Neill at Henry Ford Hospital, as well as the other investigators involved in this trial. The dedication from these investigators has led to the completion of patient enrollment and will enable data analysis and submission for a HDE with anticipated approval in early 2015." Abiomed added that after the completion of patient enrollment, the Company will submit the compiled data and seek approval for a Continuous Access Protocol to enable the 15 approved Impella RP sites to continue enrolling a limited number of patients that meet the criteria and protocol. The full analyst notes on Abiomed Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03272014/ABMD/report.pdf

--

Geron Corporation Analyst Notes 

On March 20, 2014, Geron Corp. (Geron) announced that patients currently enrolled in the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST) who are deriving clinical benefit may continue imetelstat treatment under a partial clinical hold placed by the U.S. Food and Drug Administration (FDA). The Company informed that a partial clinical hold means that no new patients may be enrolled into the Myelofibrosis IST, and patients currently enrolled must demonstrate that they are deriving clinical benefit in order to continue taking imetelstat. Geron stated that the reason cited by the FDA for the partial clinical hold was that a safety signal of hepatotoxicity had been identified in clinical trials of imetelstat, and that it is not known if this hepatotoxicity is reversible. The Company added that it expects to provide an update regarding its clinical hold during the first quarter conference call. The full analyst notes on Geron Corporation are available to download free of charge at:

http://www.AnalystsReview.com/03272014/GERN/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review